ACCESSWIRE

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Outlook Therapeutics, Inc.(OTLK) of a Class Action Lawsuit and an Upcoming Deadline

NEW YORK, NY / ACCESSWIRE / November 21, 2023 / If you suffered a loss on your Outlook Therapeutics, Inc. (NASDAQ:OTLK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:

https://zlk.com/pslra-1/outlook-lawsuit-submission-form?prid=56649&wire=1

or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced shareholder advocates.

THE LAWSUIT: A class action securities lawsuit was filed against Outlook Therapeutics, Inc. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between December 29, 2022 and August 29, 2023.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) there was a lack of substantial evidence supporting the Company's lead product candidate, ONS-5010, as a treatment for wet age-related macular degeneration; (ii) Outlook and/or its manufacturing partner had deficient chemistry manufacturing and controls and other manufacturing issues for ONS-5010, which remained unresolved at the time the ONS-5010 biologics license application ("BLA") was resubmitted to the U.S. Food and Drug Administration ("FDA"); (iii) as a result of all the foregoing, the FDA was unlikely to approve the ONS-5010 BLA in its present form; (iv) accordingly, ONS-5010's regulatory and commercial prospects were overstated; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

WHAT'S NEXT? If you suffered a loss in Outlook stock during the relevant time frame - even if you still hold your shares - go to https://zlk.com/pslra-1/outlook-lawsuit-submission-form?prid=56649&wire=1 to learn about your rights to seek a recovery. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
https://zlk.com/

SOURCE: Levi & Korsinsky, LLP



View source version on accesswire.com:
https://www.accesswire.com/807586/shareholder-alert-levi-korsinsky-notifies-shareholders-of-outlook-therapeutics-incotlk-of-a-class-action-lawsuit-and-an-upcoming-deadline

NOTE: This content is not written by or endorsed by "KLFY", its advertisers, or Nexstar Media Inc.

For inquiries or corrections to Press Releases, please reach out to Accesswire.